Shanu Modi
莎努·莫迪
MD
Medical Oncologist, Breast Medicine Service乳腺医学科肿瘤内科医生
👥Biography 个人简介
Leading investigator of DESTINY-Breast04 and DESTINY-Breast06 trials establishing trastuzumab deruxtecan as standard of care for HER2-low metastatic breast cancer, redefining HER2-low as a new therapeutic category.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HER2-Low Breast Cancer
Led pivotal DESTINY-Breast04 trial showing T-DXd significantly improved PFS and OS in HER2-low metastatic breast cancer, creating a new treatment paradigm for this previously undifferentiated population.
Representative Works 代表性著作
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer (DESTINY-Breast04)
New England Journal of Medicine (2022)
Landmark trial demonstrating T-DXd benefit in HER2-low breast cancer, published in NEJM and presented at ASCO 2022.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 莎努·莫迪 的研究动态
Follow Shanu Modi's research updates
留下邮箱，当我们发布与 Shanu Modi（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment